Don't confuse this URL with some dot-com selling this, that, or the other doodad. What it does sell (and manufacture) is branded and generic medicines. Its core products include Qualaquin (for malaria), Colcrys (a treatment for gout), Fibricor (to manage cholesterol and triglyceride), and Bactrim (a broad-spectrum antibiotic). Each of those drugs is marketed through URL's branded pharmaceutical business, AR Scientific. URL's pipeline also has several candidates in various stages of development. The company, which traces its roots back to 1946, was acquired by Japanese firm Takeda Pharmaceutical in 2012.

Takeda purchased URL for some $800 million to expand its line of gout treatments, as well as its operational base in the US market. URL is managed by the US-based Takeda organization and benefits from access to Takeda's broader marketing and sales organization in North America. In late 2012 Takeda agreed to sell URL Pharma's generic business to Sun Pharmaceutical.

Historically, URL Pharma focused solely on producing generic products, but as generic drug manufacturing shifted from the US to Asia (which drove the price of generic drugs down) in the mid-2000s, the company had to shift its own focus towards branded pharmaceuticals. While it does still manufactures some generic products, the company has moved many of its resources over to AR Scientific. As such, its branded division's revenue has been on the rise, accounting for more than 80% of URL Pharma's total revenue in 2010 (as opposed to about 40% just two years earlier). Much of the division's recent success can be attributed to its Fibricor and Colcrys products, which were introduced to the US market in 2009.

URL invests between $50 million and $70 million annually to conduct research on both novel drug treatments and existing drug formulas with other pharmaceutical companies. The company has a pipeline in the works that includes drugs to treat seizures, insomnia, and high cholesterol, among others. URL is working with Mutual Pharmaceutical Company on the generic pipeline drugs.

- Show Less + Show Full Description

Company News and Press Releases

- Show Less + Show More News and Press Releases


1100 Orthodox St
Philadelphia, PA 19124-3168
Phone: 1 (215) 288-6500


  • Employer Type: Private
  • Senior Vice President Of Of Business Development And Market Access: Gregory Hayer
  • Senior Scientist: Qing Sun
  • Vice President Research And Development: Henry Wolfe

Major Office Locations

  • Philadelphia, PA